Owens & Minor: UBS downgrades to 'Neutral' Rating, The Target Price is $4

UBS downgrades 'Neutral' rating on Owens & Minor(OMI), compare with the 'Buy' previously.

The target price is $4, compare with $7 previously.

[Recent Rating]

Date	Agency	Change	Rating	Rating （previously）	Target Price	Target Price（previously）
2025-11-03	UBS	Downgrades	Neutral	Buy	$4	$7

[Recent Earning Results] Owens & Minor posted the Q3 of its 2025 financial results on 10/31/2025, reporting total revenue of USD 2053.07 million in the first three quarters, up 3.42% from USD 1985.09 million year over year, reporting net income of USD -1044.32 million in the first three quarters, expanding 1468.75% from USD -66.57 million year over year.

[Company Profile] Owens & Minor, Inc. a Fortune 500 company headquartered in Richmond, Virginia. The company is a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services to deliver and sustained value across the breadth of the industry.